MedTrace Logo

Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)

NCT05253118 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-04-24

No results posted yet for this study

Summary

Relapsed or refractory primary DLBCL of the CNS

Conditions

Interventions

DRUG

Tislelizumab

Tislelizumab (BGB-A317) 200mg will be administered on Day 1 of each 21-day cycle (once every 3 weeks) in combination with pemetrexed.

DRUG

Pemetrexed

Pemetrexed 500 mg/m2 will be administered on Day 1 of each 21-day cycle (once every 3 weeks).

Sponsors & Collaborators

  • Gyeongsang National University Hospital

    collaborator OTHER

  • Kyunghee University Medical Center

    collaborator OTHER

  • Inje University Haeundae Paik Hospital

    collaborator OTHER

  • Chungnam National University Hospital

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Tae Min Kim, PhD., M.D. · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-18
Primary Completion
2026-12-28
Completion
2026-12-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05253118 on ClinicalTrials.gov